| abstract |
Disclosed is a therapeutic agent that targets and antagonizes CD40L with non-antibody alternatives instead of targeting CD40L with conventional antibodies that raises safety concerns. A tenascin-3FnIII domain-based scaffold that specifically binds to CD40L, as well as a genetically engineered variant with increased affinity for the target. Genetically engineered scaffolds used as preventive, diagnostic, or therapeutic agents, particularly in therapeutic use against SLE and other autoimmune diseases and conditions. [Selection figure] None |